Skip to main content

Table 1 Patients' characteristics at baseline

From: Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz

Variable N(%)
Age, years [mean (SD)] 41.6 (11.9)
Males 61 (81.3)
Risk factor IVDU 6 (8)
BMI (< 25 Kg/m2) 39 (52.7)
Viral load > 100.000 copies/mL 26 (34.7)
CD4 T cell count < 200 cells/mm3 17 (22.7)
CD4/CD8 ratio < 0.4 42 (56)
Cigarette smokers 35 (46.7)
HCV Ab positive 11 (14.7)
CDC 93 clinical class A 46 (65.7)
HAART:  
   • TDF/FTC + EFV 33 (44)
   • TDF/FTC + ATV/r 42 (56)
Phosphoraemia < 2.7 mg/dL 19 (25.3)
1,25 (OH)2 Vitamin D < 11 pg/mL 19 (25.3)
Hyperparathyroidism (> 65 pg/mL) 4 (5.3)
eGFR creatinine * < 90 mL/min 26 (34.6)
eGFR cystatin C * < 90 mL/min 15 (20.5)
OC, ng/mL [mean (SD)] 19.86 (10)
CTx, ng/mL [mean (SD)] 0.43 (0.26)
OPG, ng/mL [mean (SD)] 0.83 (0.41)
  1. N number, SD standard deviation, IVDU intra-venous drug users, BMI body mass index, HAART highly active antiretroviral therapy, TDF tenofovir, FTC emtricitabine, EFV efavirenz, ATV/r atazanavir/ritonavir, eGFR estimated glomerular filtration rate, OC osteocalcin, CTx C-terminal cross-laps, OPG osteoprotegerin